Sustained Remission From Weeks 16 to 52 and Weeks 24 to 52 in Patients Treated With Sarilumab: Post-hoc Analysis of SAPHYR Trial in Patients With Polymyalgia Rheumatica.
Sustained Remission From Weeks 16 to 52 and Weeks 24 to 52 in Patients Treated With Sarilumab: Post-hoc Analysis of SAPHYR Trial in Patients With Polymyalgia Rheumatica.
- The poster presents post-hoc results from the SAPHYR study on the proportion of patients achieving sustained remission and its components at weeks 16 and 24 up to week 52.A higher proportion of patients in the sarilumab arm vs comparator arm achieved sustained remission and its individual components when assessed from week 16 and week 24 up to week 52. Most patients who achieved sustained remission did so rapidly by week 12 with some additional responses observed between weeks 12 and 24. The actual mean daily GC dose administered during the study was lower in the sarilumab arm vs comparator.
- Poster Source: Data included in this poster were originally presented at the European Alliance of Associations for Rheumatology (EULAR) 2023, May 31-Jun 03, Milan, Italy.
Remission, Glucocorticoid Toxicity, Health-Related Quality of Life, and Safety Outcomes in Patients With Renal Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
Remission, Glucocorticoid Toxicity, Health-Related Quality of Life, and Safety Outcomes in Patients With Renal Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
Long-term safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: 5-year results from a phase 2b study and its open-label extension
Long-term safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: 5-year results from a phase 2b study and its open-label extension
Dr. Alexis Ogdie, MD, Author
Dr. Alexis Ogdie, MD, Author
Durability of Response Among Psoriatic Arthritis (PsA) Patients Using Biological/Targeted Synthetic Disease-Modifying Antirheumatic Drugs (b/tsDMARDs) in the CorEvitas PsA/Spondyloarthritis Registry
Durability of Response Among Psoriatic Arthritis (PsA) Patients Using Biological/Targeted Synthetic Disease-Modifying Antirheumatic Drugs (b/tsDMARDs) in the CorEvitas PsA/Spondyloarthritis Registry
Sponsorship: Sponsored by CorEvitas, LLC. And UCB Pharma.
Presenters: Alexis Ogdie (narrating author), Chao Song, Nicole Middaugh, Maya Marchese, Melissa Eliot, Silky W. Beaty, Robert Low, Philip J. Mease
Abstract: This study aimed to describe the durability of treatment response over 24 months following achievement of 50% improvement in the modified American College of Rheumatology response (mACR50), and factors associated with the response, among patients in the CorEvitas Psoriatic Arthritis (PsA)/Spondyloarthritis (SpA) Registry treated with biological/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs).
Abstract source: Originally presented at ACR 2023
Pfizer
Pfizer
